Akt inhibitors: mechanism of action and implications for anticancer therapeutics

被引:30
|
作者
Bhutani, Jaikrit [1 ]
Sheikh, Asfandyar [2 ,4 ]
Niazi, Asfandyar Khan [3 ]
机构
[1] Post Grad Inst Med Sci, Rohtak, Haryana, India
[2] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[3] Shifa Coll Med, Islamabad, Pakistan
[4] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan
来源
关键词
SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-SURVIVAL; KINASE; GROWTH; CARCINOMAS; EXPRESSION; ONCOGENE; PATHWAY; GLIOBLASTOMAS;
D O I
10.1186/1750-9378-8-49
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride
    Maolin Guo
    Zijian Guo
    Peter Sadler
    JBIC Journal of Biological Inorganic Chemistry, 2001, 6 : 698 - 707
  • [42] The Molecular Mechanism of HDAC Inhibitors in Anticancer Effects
    Gaofeng Bi and Guosheng Jiang Department of Hemato-oncology
    Cellular&MolecularImmunology, 2006, (04) : 285 - 290
  • [43] The Molecular Mechanism of HDAC Inhibitors in Anticancer Effects
    Bi, Gaofeng
    Jiang, Guosheng
    CELLULAR & MOLECULAR IMMUNOLOGY, 2006, 3 (04) : 285 - 290
  • [44] Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors
    Park, Hye-Kyung
    Jeong, Hanbin
    Ko, Eunhwa
    Lee, Geumwoo
    Lee, Ji-Eun
    Lee, Sang Kwang
    Lee, An-Jung
    Im, Jin Young
    Hu, Sung
    Kim, Seong Heon
    Lee, Ji Hoon
    Lee, Changwook
    Kang, Soosung
    Kang, Byoung Heon
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (17) : 7569 - 7578
  • [45] Anticancer effect of Howiinol A and its mechanism of action
    Xu, CX
    He, JH
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 1999, 2 (01) : 1 - 19
  • [46] Anticancer properties and mechanism of action of the quassinoid ailanthone
    Bailly, Christian
    PHYTOTHERAPY RESEARCH, 2020, 34 (09) : 2203 - 2213
  • [47] Texanes -: Anticancer drug with unique mechanism of action
    Borek-Dohalská, L
    Stiborová, M
    CHEMICKE LISTY, 2000, 94 (04): : 226 - 229
  • [48] SURAMIN - AN ANTICANCER DRUG WITH A UNIQUE MECHANISM OF ACTION
    STEIN, CA
    LAROCCA, RV
    THOMAS, R
    MCATEE, N
    MYERS, CE
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 499 - 508
  • [49] Mechanisms of selective anticancer action of histone deacetylase inhibitors
    Insinga, A
    Minucci, S
    Pelicci, PG
    CELL CYCLE, 2005, 4 (06) : 741 - 743
  • [50] Novel mechanism of action (nMoA) compounds in therapeutics discovery
    Schreiber, Stuart
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250